04/08/2025
A surprising new study suggests that Parkinson’s disease doesn't begin in your brain.
According to new evidence uncovered by researchers in a study published in Nature Neuroscience, it may be caused by the kidneys
The team found that a key protein involved in Parkinson’s, called alpha-synuclein, can build up in the kidneys and travel to the brain through nerve connections, especially when kidney function is poor. This shifts the focus away from the brain as the starting point and suggests that chronic kidney disease might silently trigger changes that later affect the brain. Alpha-synuclein is known to cause damage when it misfolds and clumps, forming toxic deposits seen in Parkinson’s and similar disorders.
In tissue samples from people with Parkinson’s or kidney disease, the researchers found these misfolded proteins in kidney nerves and, in some cases, even in brain regions linked to the disease. In animal tests, healthy kidneys cleared the protein quickly, but in mice with kidney failure, the protein lingered and eventually spread to the brain, where it caused damage and movement problems.
The researchers also showed that cutting the kidney’s nerve supply blocked this spread entirely. Additional experiments confirmed that red blood cells, which carry much of the protein, may worsen the problem when kidney disease is present. Mice with blood cells that didn’t produce alpha-synuclein had less brain damage, unless the harmful protein was directly injected. The overall findings suggest that when kidneys can’t filter properly, alpha-synuclein can build up, deposit in nerves, and travel to the brain, setting the stage for Parkinson’s. This could explain why people with chronic kidney disease face a higher risk. However, not all cases of Parkinson’s begin this way, and the kidney-brain link may not apply to everyone. More studies are needed to see how this process works in people over time.
source
Yuan, X., Nie, S., Yang, Y. et al. Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease. Nat Neurosci 28, 577–588 (2025).
image: Neurodegeneration Imaging Group, King's College London